Zur Unternehmensseite

Veröffentlichungen

Publikationen aus der Neurologie

Originalartikel:

1. Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hübers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Großkreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC. Prognostic factors in ALS: a comparison between Germany and China. J Neurol 2019;266:1516-1525   

2. Müller K, Brenner D, Weydt P, …German ALS network MND-NET (u.a. Wolf J). Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry 2018;89:817-827   

3. Wolf J  Safer A, Maschke M, Nix WA, Wöhrle JC, Grau AJ. Epidemiologie der Amyotrophen Lateralsklerose: Daten aus dem ALS-Register Rheinland-Pfalz. Ärzteblatt Rheinland-Pfalz 2018;6:22-23  

4. Brenner D, Yilmaz R, Müller K, …German Network MND-Net (u.a. Wolf J). Hot-spot KIF5A mutations cause familial ALS. Brain 2018;141:688-697   

5. Funke A, Spittel S, Grehl T, Großkreutz J, Kettemann D, Petri S, Weyen U, Weydt P, Dorst J, Ludolph A, Baum P, Oberstadt M, Jordan B, Hermann A, Wolf J, Boentert M, Walter B, Gajewski N, Maier A, Münch C, Meyer T. Assistive technology devices in Amyotrophic Lateral Sclerosis - analysis of 4 years of platform-based case management. Amyotroph Lat Scler Frontotemp Degeneration 2018;19:342-350   

6. Van den Berg L, Van Damme P, Svenstrup K, Karlsborg M, Laaksovirta H, Salachas F, Corcia P, Couratier P, Desnuelle C, Grosskreutz J, Meyer T, Petri S, Koch JC, Weydt P, Wolf J,  Grehl T, Ludolph A, Hardiman O, Chiò A, Silani V, van der Kooi A, Holmøy T,  Kleveland G, Tysnes OB, Kuźma-Kozakiewicz M, de Carvalho M, Chandran S, Koritnik B, Mora J, Povedano M, Andersen P,  Mitre Ropero B, Nygren I, Staaf G, Ingre C, Danielsson O, Weber M, Shaw P, McDermott C, Talbot K, Al-Chalabi A. ENCALS statement on edaravone. Amyotroph Lat Scler Frontotemp Degeneration 2017;18:471-474   

7. Van Doormaal PC, Ticozzi N, Weishaupt JH, Kenna K, Diekstra FP, Verde F, Andersen PM, Dekker AM, Tiloca C, Marroquin N, Overste DJ, Pensato V, Nürnberg P, Pulit SL, Schellevis RD, Calini D, Altmüller J,  Francioli LC, Castellotti B, Motameny S, Ratti A, Wolf J, Gellera C, Ludolph AC, Van den Berg LH, Kubisch C, Landers JE, Veldink JH, Silani V, Volk AE. The role of de novo mutations in the development of amyotrophic lateral sclerosis. Human Mutation 2017:38:1534-1541   

8. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Todesursachen bei Amyotropher Lateralsklerose: Ergebnisse aus dem ALS-Register Rheinland-Pfalz. Nervenarzt 2017;88:911-918   

9. Wolf J, Safer A. Amyotrophe Lateralsklerose: Was die ALS-Phänotypen für die Prognose bedeuten. Neurotransmitter 2017;28:29-32   

10. Wolf J. Sein härtester Kampf. Todesursachen bei der ALS. Ärzte-Woche 2017;16:4-5   

11. Wolf J,  Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Factors predicting survival in ALS patients - Data from a population-based registry in Rhineland-Palatinate, Germany. Neuroepidemiology 2015;44:149-155   

12. Dorst J, Dupuis L, Petri S, Kollewe K, Abdulla S, Wolf J, Weber M, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol 2015; 262:849-58   

13. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients - data from a population-based registry. BMC Neurology 2014;14:197  

14. Wolf J, Safer A, Wöhrle JC, Nix WA, Maschke M, Grau AJ. Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis - Data from a population-based registry. J Neurol Sci 2014;345:164-7   

15. Wolf J, Wöhrle JC, Palm F, Nix WA, Maschke M, Safer A, Becher H, Grau AJ. Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. Amyotroph Lat Scler Frontotemp Degeneration 2014;15:269-74   

16. Palm F, Kraus M, Safer A, Wolf J, Chibuzor J, Becher H, Grau AJ. Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt). BMC Neurology 2014;14:199   

17. Urbanek C, Palm F, Buggle F, Wolf J, Safer A, Becher H, Grau AJ. Recent surgery or invasive procedures and the risk of stroke. Cerebrovasc Dis 2014;38:370-376   

18. Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R. Peripheral neuropathy as initial manifestation of primary systemic vasculitides. J Neurol 2013;4:1061-70   

19. Palm F, Dos Santos M, Urbanek C, Greulich M, Zimmer K, Safer A, Grau AJ, Becher H. Stroke seasonality associations with subtype, etiology and laboratory results in the Ludwigshafen Stroke Study (LuSSt). Eur J Epidemiol 2013;28:373-81   

20. Palm F, Henschke N, Wolf J, Zimmer K, Safer A, Schröder RJ, Inselmann G, Brenk P,  Becher H, Grau AJ. Intracerebral hemorrhage in a population-based stroke registry (LuSSt) Incidence, aetiology, functional outcome and mortality. J Neurol 2013;260:2541-50   

21. Palm F, Kleemann T, Dos Santos M, Urbanek C, Buggle F, Safer A, Hennerici MG, Becher H, Zahn R, Grau AJ. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study). CHADS(2), CHA(2)DS(2)-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol 2013;20:117-23   

22. Palm F, Urbanek Ch, Wolf J, Buggle F, Kleemann T, Hennerici MG, Inselmann G, Hagar M, Safer A, Becher H, Grau AJ. Etiology, risk factors and sex-differences in ischemic stroke in the Ludwigshafen Stroke Study (LuSSt), a population-based stroke registry. Cerebrovasc Dis 2012;33:69-75   

23. Wolf J, Obermaier-Kusser B, Jacobs M, Milles C, Mörl M, Müller H, Grau AJ, Bauer MF. A new mitochondrial point mutation in the transfer RNA (Lysine) gene causing a clinical phenotype of progressive external ophthalmoplegia with impaired respiratory regulation. J Neurol Sci 2012;316:108-111   

24. Dos Santos M, Grond-Ginsbach C, Aksay SS, Chen B, Tchatchou S, Wolf NI, van der Knaap MS, Grau AJ. Adult-onset autosomal dominant leukodystrophy due to LMNB1 gene duplication. J Neurol 2012;259:579-81   

25. Tomaschütz L, Dos Santos M, Schill J, Palm F, Grau A. Recurrent amaurosis fugax in a patient after stanford type a dissection depending on blood pressure and haemoglobin level. Case Rep Vasc Med 2012;2012:254204   

26. Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurologic complications of Churg-Strauss syndrome.  Eur J Neurol 2010;17:582-588   

27. Wolf J, Maschke M, Nix WA, Wöhrle JC, Grau AJ. Amyotrophe Lateralsklerose-Register: Startschuss für ein landesweit einzigartiges Projekt. Neurotransmitter 2010;4:16-17   

28. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, Schielke E, Schmutzhard E, De Gans J, Chung CH, Luntz S, Hacke W, Meyding-Lamadé U, and GACHE Investigators (u.a. Wolf J). Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. BMC Neurol 2008;8:40   

29. Wolf J, Jacobi C, Breer H, Grau A. Das Chediak-Higashi-Syndrom. Nervenarzt 2006;77:148-157   

30. Wolf J. Schlaganfälle im jungen Erwachsenenalter. Neurotransmitter 2006;6:64-70   

31. Wolf J, Niedermaier N, Lowitzsch K. Schlaganfälle im jungen Erwachsenenalter. Nervenheilkunde 2005;24:681-5   

32. Sartorius A, Wolf J, Henn F. Lithium and ECT - concurrent use still demands attention. World J Biol Psychiatry 2005;6:313-17   

33. Wolf J, Sartorius A, Alm B, Henn F. Clozapine-induced lupus erythematosus. J Clin Psychopharmacol 2004;24:236-8   

34. Wolf J, Niedermaier N, Bergner R, Lowitzsch K. Zerebrale Vaskulitis als Erstmanifestation eines systemischen Lupus erythematodes. Dtsch Med Wschr 2001;126:947-50

Buchbeiträge:

1. Wolf J, Grau A. Metabolische Hirnstammerkrankungen in: Erkrankungen des Hirnstamms, Herausgeber: Urban P., Schattauer-Verlag 2008, 290-310   

2. Wolf J, Grau A. Metabolic Brainstem Diseases in: Brainstem Disorders, Editors: Urban P, Caplan LR, Springer-Verlag 2011, 303-326  

Wichtige wissenschaftliche Präsentationen:

1. Wolf J. Vaskulitische Neuropathien - Neues zu Diagnostik und Therapie. 92. Kongress der Dt. Gesellschaft für Neurologie, Stuttgart, 25.09.2019   

2. Witzel S, Hübers A, Michels S, Petri S, Lingor P, Koch C, Hermann A, Günther R, Wolf J, Weishaupt JH, Otto M, Ludolph AC. Therapie mit Edaravone bei der amyotrophen Lateralsklerose. Kongress des medizinisch-wissenschaftlichen Beirats der Dt. Gesellschaft für Muskelkranke, Göttingen, 10.05.2019   

3. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ.  Causes of death in amyotrophic lateral sclerosis. Results from the Rhineland-Palatinate ALS registry. Kongress des European Network to Cure ALS (ENCALS), 20.06.2018, Oxford/Großbritannien   

4. Wolf J. Epidemiologie der Amyotrophen Lateralsklerose in Deutschland. Festvortrag zur Verleihung des Christa-Lorenz-ALS-Forschungspreises, 13.12.2017, Universitätsklinikum Magdeburg   

5. Funke A, Spittel S, Grehl T, Großkreutz J, Kettemann D, Petri S, Weyen U, Weydt P, Dorst J, Ludolph A, Baum P, Oberstadt M, Jordan B, Hermann A, Wolf J, Boentert M, Walter B, Gajewski N, Maier A, Münch C, Meyer T. Assistive technology devices in Amyotrophic Lateral Sclerosis - analysis of 4 years of platform-based case management. International Symposium on ALS/MND. 07.12.2017, Boston/USA.   

6. Bajwa A, Rittmann M, Behrang-Nia M, Martins Dos Santos M, Homenu W, Becker H, Dorner M, Lücke T, Wolf J. Wundbotulismus - eine wichtige Differentialdiagnose bei Drogenabhängigen. Jahrestagung der Deutschen Gesellschaft für Neurointensiv- und Notfallmedizin (ANIM). 17.02.2017, Wien   

7. Alkhasova N, Rittmann M, Wolf J. Adulte Manifestation einer Mitochondrienmembranprotein-assoziierten Neurodegeneration. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim   

8. Sharifzadeh Tadi A, Rittmann M, Wolf J. Late onset-Variante einer Globoidzell-Leukodystrophie (Morbus Krabbe) - Fallbericht. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim  (Posterpreis der DGN)   

9. Wolf J. Aktuelle diagnostische und therapeutische Optionen bei vaskulitischen Neuropathien. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim   

10. Wolf J, Safer A, Wöhrle J, Palm F, Nix W, Maschke M, Grau A. Prognosefaktoren bei Erstdiagnose einer Amyotrophen Lateralsklerose. Kongress des Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke. 18.06.2015, Bochum   

11. Wolf J, Safer A, Wöhrle J, Palm F, Nix W, Maschke M, Grau A. Prognostische Bedeutung unterschiedlicher ALS-Phänotypen. Kongress der Deutschen Gesellschaft für Neurologie. 25.09.2015, Düsseldorf   

12. Safer A, Palm F, Nix W, Maschke M, Wöhrle J, Grau AJ, Wolf J. Prognosefaktoren für das Überleben bei amyotropher Lateralsklerose - Daten aus dem ALS-Register Rheinland-Pfalz. Jahrestagung der Dt. Gesellschaft für Epidemiologie. 18.09.2014, Ulm   

13. Wolf J, Wöhrle J, Palm F, Nix W, Maschke M, Becher H, Grau A. Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. International Symposium on ALS/MND. 07.12.2013, Mailand/Italien   

14. Wolf J, Wöhrle J, Palm F, Nix W, Maschke M, Becher H, Grau A. Epidemiologie der amyotrophen Lateralsklerose in Deutschland - das ALS-Register Rheinland-Pfalz. Kongress der Deutschen Gesellschaft für Neurologie. 20.09.2013, Dresden

Publikationen aus der Gastroenterologie, Hepatologie und Endokrinologie

Publikationen aus der Klinik für Kardiologie, Angiologie und Diabetesfolgeerkrankungen

Publikationen aus der Sektion Onkologie

Prof. Dr. med. Manfred Hensel | Stand 25.10.2018

Originalarbeiten mit Erst- oder Letztautorenschaft

  • Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, Stangel M, Fasshauer M, Gold R, Hensel M. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol. 2017 Aug;99(2): 169-177.  
  • Welz T, Wyen C, Hensel M. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. Oncol Res Treat. 2017;40(3):120-127. Review.
  • Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, Wyen C, Hensel M; German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ); German AIDS Society (DAIG). Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). Ann Hematol. 2014 Jun;93(6):913-21. doi: 10.1007/s00277-014-2058-4. Epub 2014 Mar 29. Erratum in: Ann Hematol. 2014 Aug;93(8):1445.
  • Hensel M, Brust J, Plöger C, Schuster D, Memmer ML, Franz-Werner J, Feustel HP, Karcher A, Fuxius S, Mosthaf FA, Rieger M, Ho AD, Witzens-Harig M.  Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol. 2012 Dec;91(12):1923-8.
  • Hensel M, Goetzenich A, Lutz T, Stoehr A, Moll A, Rockstroh J, Hanhoff N, Jäger H, Mosthaf F. HIV and Cancer in Germany. Dtsch Arztebl Int. 2011 Feb;108(8):117-22. Epub 2011 Feb 25.
  • Kornacker M, Kornacker B, Schmitt C, Leo E, Ho AD, Hensel M. Commercial LightCycler(R)-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma. Ann Hematol. 2009 Jan;88(1):43-50. Epub 2008 Jul 18.
  • Hensel, M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer. 2009 Jan;17(1):47-52. Epub 2008 May 6.
  • Schweizer C, Reu FJ, Ho AD, Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.
  • Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007 Jul;8(7):658-60. No abstract available.
  • Hensel M, Dreger P, Ho AD. IgM-Gammopathie: Differentialdiagnose, Klinik und Therapie. Dtsch Arztebl 2007; 104(26): A-1907 / B-1684 / C-1620
  • Hensel M, Zoz M, Giesecke C, Benner A, Neben K, Jauch A, Stilgenbauer S, Ho AD, Krämer A. High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. Int J Cancer. 2007 Sep 1;121(5):978-83.
  • Ho AD, Hensel M. Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol. 2006 Apr;2(2):169-83. Review.
  • Ho AD, Hensel M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol. 2006 Apr;43(2 Suppl 2):S2-10. Review.
  • Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma. 2005 Sep;6(2):131-5.
  • Hensel M, Buss EC, Tiemann M, Parwaresch R, Libicher M, Fruehauf S, Ho AD. Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndrome. Eur J Haematol. 2004 Mar;72(3):217-21.
  • Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia.
  • Br J Haematol. 2003 Aug;122(4):600-6. PMID: 12899715 [PubMed - indexed for
  • Hensel M, Ho AD. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol. 2003 May;73(1):37-40.
  • Hensel M, Ho AD, Bastert G, Schneeweiss A. Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer. Ann Oncol. 2003 Feb;14(2):341. No abstract available.
  • Hensel M, Fiehn C, Ho AD. [Stem cell transplantation in primary systemic vasculitis] Med Klin (Munich). 2003 Jan 15;98(1):13-8. Review. German.
  • Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer. 2002 Jul 20;100(3):290-6.
  • Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol. 2002 Feb;13(2):209-17.
  • Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells. 2002;20(1):32-40.
  • Schneeweiss A*, Hensel M*, Goerner R, Khbeis T, Hohaus S, Egerer G, Solomayer E, Haas R, Grischke EM, Bastert G, Ho AD. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. (*shared first author). Stem Cells. 2001;19(2):151-60.
  • Hensel M, Breitbart A, Ho AD. Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement. N Engl J Med. 2001 Jan 4;344(1):69. No abstract available

Originalarbeiten mit Ko-Autorenschaft

  • Kriegsmann K, Rieger M, Schwarzbich MA, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD, Witzens-Harig M, Wuchter P. Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol. 2018 Jul;101(1):12-20.
  • Reiser M, Dörfel S, Hensel M, Hoesl M, Jordan WO, Koenigsmann M, Meyer D, Reichert D, Schwarzer A, Marquardt M, Kellershohn K, Jentsch-Ullrich K. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. Eur J Haematol. 2018 May;100(5):455-464.
  • Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018 Jan 2;128(1)
  • Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Feb;58(2):399-407.
  • Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord. 2016 May;9(3):165-79.
  • Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015 Dec;171(5):710-9.  
  • Herth I, Hensel M, Rieger M, Horstmann K, Hiddemann W, Dreyling M, Koniczek S, Witzens-Harig M, Ho AD. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. 2015 Jan;56(1):97-102.
  • Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C.  HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
  • Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.Leukemia. 2013 Sep;27(9):1949-52. Free PMC Article
  • Martin Stangel, Ulrich Baumann, Michael Borte, Maria Fasshauer, Manfred Hensel, Dörte Huscher, Wilhelm Kirch, David Pittrow, Marcel Reiser, Ralf Gold. Treatment of Neurological Autoimmune Diseases With Immunoglobulins: First Insights From the Prospective SIGNS Registry. Martin Stangel, Ulrich Baumann, Michael Borte. J Clin Immunol. 2013 Jan;33 Suppl 1:S67-71.
  • McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig.  Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. Am J Hematol. 2012 Jun 8. doi: 10.1002/ajh.23286. [Epub ahead of print]
  • McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig M. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. Am J Hematol. 2012 Jun 8. doi: 10.1002/ajh.23286. [Epub ahead of print] No abstract available.
  • Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. Blood. 2012 Apr 5. [Epub ahead of print]
  • Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W; Liste der aktuell beitragenden Zentren, sortiert nach Postleitzahlen (mindestens ein Patient zum 1.3.2012). [Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80. Epub 2012 Mar 20. Review. German.
  • Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K.Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.BMC Cancer. 2011 Feb 26;11:87.
  • Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P.Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009 Apr;20(4):722-8. Epub 2009 Jan 29.
  • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.Lancet. 2010 Oct 2;376(9747):1164-74.
  • Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M. Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods. Med Klin (Munich). 2010 Sep;105(9):647-51. Epub 2010 Sep 28. German.
  • Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia.J Clin Oncol. 2010 Oct 10;28(29):4473-9. Epub 2010 Aug 9.
  • McClanahan F, Hielscher T, Rieger M, Hensel M, Neben K, Hillengass J, Herfarth K, Ho AD, Witzens-Harig M. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.Eur J Haematol. 2010 Jul;85(1):11-9. Epub 2010 Mar 16.
  • Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.J Clin Oncol. 2009 Aug 20;27(24):3994-4001. Epub 2009 Jul 13.
  • Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.Ann Oncol. 2009 Apr;20(4):722-8. Epub 2009 Jan 29.
  • Witzens-Harig M, Reiz M, Heiß C, Benner A, Hensel M, Neben K, Dreger P, Kraemer A, Ho AD. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol. 2009 Jan;88(1):51-7. Epub 2008 Jul 30.
  • Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).Ann Hematol. 2008 Sep;87(9):717-26. Epub 2008 Jun 28.
  • Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, Hensel M, Wildemann B. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.Blood. 2008 Jan 15;111(2):761-6. Epub 2007 Oct 29.
  • Dreger P, Rieger M, Seyfarth B, Hensel M, Kneba M, Ho AD, Schmitz N, Pott C. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007 Jan;92(1):42-9.
  • Witzens-Harig M, Heilmann C, Hensel M, Kornacker M, Benner A, Haas R, Fruehauf S, Ho AD. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.Stem Cells. 2007 Jan;25(1):228-35.
  • Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006 Dec;47(12):2558-66.
  • Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.Cancer Invest. 2006 Oct;24(6):593-600.
  • Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Gotze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Dohner K, Dohner H. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial. Leukemia. 2006 Apr;20(4):748-50.
  • Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.Int J Cancer. 2006 Sep 15;119(6):1377-82.
  • Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jaeger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Doehner H, Brittinger G, Emmerich B, Hallek M. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia.Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.
  • Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?Leuk Res. 2006 Dec;30(12):1563-8. Epub 2006 Mar 10.
  • Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M, Ho AD, Leo E. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.Leuk Res. 2006 Jun;30(6):745-50. Epub 2005 Nov 16.
  • Maurer B, Hensel M, Max R, Fiehn C, Ho AD, Lorenz HM. Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.Ann Rheum Dis. 2006 Jan;65(1):127-9. Epub 2005 May 26.
  • Nikendei C, Schilling T, Nawroth P, Hensel M, Ho AD, Schwenger V, Zeier M, Herzog W, Schellberg D, Katus HA, Dengler T, Stremmel W, Müller M, Jünger J. [Integrated skills laboratory concept for undergraduate training in internal medicine]. Dtsch Med Wochenschr. 2005 May 6;130(18):1133-8. German.
  • Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, Del Valle Y Fuentes F, Gotze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Dohner K, Frohling S, Dohner H. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005 Jun;19(6):978-83.
  • Bochtler T, Hensel M, Lorenz HM, Ho AD, Mahlknecht U. Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.Rheumatology (Oxford). 2005 Sep;44(9):1199. Epub 2005 Apr 26.
  • Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, Ho AD, Bastert G. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.Ann Oncol. 2004 Nov;15(11):1627-32.
  • Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, Kipriyanov SM. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.Int J Cancer. 2004 Nov 10;112(3):509-18.
  • Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. 2004 Feb;444(2):108-18. Epub 2004 Jan 20. Review.
  • Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group.
  • Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.J Clin Oncol. 2003 Jul 15;21(14):2747-53.
  • Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Frohling S, Dohner K, Haas R, Dohner H; AML Study Group Ulm (AMLSG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003 Aug;17(8):1521-8.
  • Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Kröger N, Hensel M, Scheffold C, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.Ann Hematol. 2002;81 Suppl 2:S47-8.
  • Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group. Phase-II Study of a combined Immuno-Chemotherapy using Rituximab and Fludarabine in Patients With Chronic Lymphocytic Leukemia Blood 2002 Nov 1;100(9):3115-20
  • Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, Bastert G, Ho AD. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.Bone Marrow Transplant. 2002 Oct;30(7):427-31.
  • Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.Ann Oncol. 2002 May;13(5):679-88.
  • Egerer G, Hensel M, Ho AD. Infectious complications in chronic lymphoid malignancy.Curr Treat Options Oncol. 2001 Jun;2(3):237-44. Review.
  • Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.Leukemia. 2002 Apr;16(4):581-6.
  • Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.Leuk Lymphoma. 2002 Jan;43(1):149-51.
  • Schneeweiss A, Goerner R, Hensel M, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.Biol Blood Marrow Transplant. 2001;7(6):332-42.

Buchbeiträge

  • Hensel M., Witzens-Harig M.: Niedrigmaligene Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten. In: Geriatrische Onkologie. Hrsg.: Ebert, Härtel, Wedding. Springer Verlag 2018
  • Hensel M.: Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance. In: HIV-associated Hematological Malignancies. Hrsg.: Hentrich, Barta. Springer Verlag 2017
  • Hensel M. Chemotherapeutika und Anästhesie. In: Anästhesie in der Traumatologie und Orthopädie. Hrsg.: Th. Frietsch, A. Weiler-Lorentz. Urban&Fischer Verlag, München 2009
  • Hinkelbein J, Feller-Heppt G, Lenz C, Hensel M, Frietsch T. Mastozytose: Pathologie und anästhesiologische Implikationen für die Praxis. 2008
  • Hensel M. Einsatz monoklonaler Antikörper bei malignen Lymphomen (Rituximab, Zevalin/Bexxar, Epratuzumab, HuMax-CD20, Galiximab). In: Antikörpertherapie in der Hämatologie und Onkologie. UNI-MED Verlag Bremen. 2007
  • Hensel M. Substitution von Immunglobulinen. In: Supportivtherapie bei malignen Erkrankungen. Herausgeber: Link; Bokemeyer, Feyer. Deutscher Ärzteverlag Köln, 2006
  • Fiehn C, Hensel M. High Dose Chemotherapy with Haematopoietic Stem Cell Transplantation in Primary Systemic Vasculitis, Behcet`s disease and Sjoegren`s Syndrome. Stem Cell Therapy for Autoimmune Disease. eds. Marmont and Burt; Landes Bioscience, Georgetown, USA. 2003

Diese Website verwendet Cookies.
Diese Webseite nutzt externe Komponenten, wie z.B. Karten, Videos oder Analysewerkzeuge, welche alle dazu genutzt werden können, Daten über Ihr Nutzungsverhalten zu sammeln. Personenbezogene Daten werden von uns nicht erhoben und bedürfen, wie z. B. bei der Nutzung von Kontaktformularen, Ihrer expliziten Zustimmung. Weitere Informationen zu den von uns verwendeten Diensten und zum Widerruf finden Sie in unseren Datenschutzbestimmungen. Ihre Einwilligung dazu ist freiwillig und für die Nutzung der Webseite nicht notwendig.